trial

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patients Who Completed the Protocol 25543 (25544)(P05777)

NCTId NCT00265343
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 306 (actual)
Sponsored by Organon and Co
Primary completion 2007-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
306 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
Quadruple
Start
2005-12
Primary completion
2007-12
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
AsenapineOlanzapine

Sponsors

Organon and CoLead Sponsor

Sites

0 total

Linked catalysts

1
6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptom Patient — primary completion2007-12

Facts & assertions

4 sourced
Enrollment
306
Phase
PHASE3
Primary Completion Date
2007-12
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
Olanzapine
drug
lead_sponsor
Organon and Co
company
indication
Schizophrenia
indication
Schizophrenia
indication